GPOs (Vizient, Premier, HealthTrust) aggregate the purchasing volume of member hospitals to negotiate price and contract terms with suppliers. Most U.S. hospitals belong to one or more GPOs. GPOs negotiate contracts for member hospitals and earn administrative fees from suppliers, which are protected by an Anti-Kickback safe harbor. Being on a GPO contract can open access to many hospitals at once. Members can still buy off contract, and value analysis committees make final product choices.

Why it matters

GPO contract status (on-contract, dual-source, sole-source) materially affects MedTech pull-through. GPOs also operate consulting, analytics, and clinical evidence services.

Common pitfalls

•MedTech manufacturers might assume GPO inclusion guarantees market adoption, but individual hospital purchasing decisions still prevail.
•Underestimating the time and resources required to secure and maintain GPO contracts can lead to missed market opportunities.
•Failing to consider the GPO's influence on supply chain stability can impact a manufacturer's ability to consistently meet demand and regulatory obligations.
•Manufacturers might overlook the need to align their quality management system processes, such as supplier management, with GPO purchasing requirements and specifications.

Sources

HSCA · HSCA
AdvaMed Code of Ethics · AdvaMed
AHRMM - Healthcare Supply Chain · AHRMM
HHS OIG group purchasing organization safe harbor (42 CFR 1001.952(j)) · Electronic Code of Federal Regulations / HHS OIG regulation

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.